Surgery During Kisunla (Donanemab) Treatment
I cannot provide specific guidance on surgery during Kisunla treatment, as none of the provided evidence addresses donanemab (Kisunla) or its perioperative management.
Critical Clarification Needed
The evidence provided discusses:
- Ribociclib (Kisqali) - a CDK4/6 inhibitor for breast cancer 1, 2, 3, 4
- Antirheumatic medications for joint replacement surgery 5, 6
- Anticoagulants (apixaban, dabigatran) for perioperative management 7, 8, 9
- Imatinib for GIST tumors 10
- Hemophilia treatments 11
None of these medications are Kisunla (donanemab), which is an anti-amyloid monoclonal antibody for Alzheimer's disease.
General Principles for Monoclonal Antibody Surgery (Based on Available Evidence)
While not specific to donanemab, the rheumatology guidelines suggest that for biologic agents:
- Surgery should ideally be planned after the end of the dosing interval when active drug levels would be lowest 5, 6
- For intravenous biologics, planning surgery when the next dose is due minimizes drug exposure during the perioperative period 5, 6
- Bridging is typically not required for biologics with predictable pharmacokinetics 7
What You Need
To properly answer this question, you would need:
- Donanemab-specific FDA labeling information
- Donanemab pharmacokinetic data (half-life, clearance)
- Clinical guidelines for perioperative management of anti-amyloid antibodies
- Data on bleeding risk or wound healing complications with donanemab
Consult the prescribing information for Kisunla and the treating neurologist before proceeding with surgery.